You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNefazodone
Accession NumberDB01149  (APRD00402)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionNefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. [Wikipedia]
Structure
Thumb
Synonyms
1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one
Nefazodona
Nefazodone
Nefazodonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Lin-nefazodonetablet200 mgoralLinson Pharma Co.2000-09-112003-11-28Canada
Lin-nefazodonetablet50 mgoralLinson Pharma Co.2000-09-112003-11-28Canada
Lin-nefazodonetablet100 mgoralLinson Pharma Co.2000-09-112003-11-28Canada
Lin-nefazodonetablet150 mgoralLinson Pharma Co.2000-09-112003-11-28Canada
Serzone-5ht2tablet150 mgoralBristol Myers Squibb Canada1994-12-312003-11-28Canada
Serzone-5ht2tablet100 mgoralBristol Myers Squibb Canada1994-12-312003-11-28Canada
Serzone-5ht2tablet200 mgoralBristol Myers Squibb Canada1994-12-312003-11-28Canada
Serzone-5ht2tablet50 mgoralBristol Myers Squibb Canada1997-07-162003-11-28Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nefazodone Hydrochloridetablet150 mg/1oralRebel Distributors Corp2003-09-16Not applicableUs
Nefazodone Hydrochloridetablet100 mg/1oralTeva Pharmaceuticals USA Inc2003-09-16Not applicableUs
Nefazodone Hydrochloridetablet50 mg/1oralAv Kare, Inc.2013-12-16Not applicableUs
Nefazodone Hydrochloridetablet50 mg/1oralTeva Pharmaceuticals USA Inc2003-09-16Not applicableUs
Nefazodone Hydrochloridetablet200 mg/1oralRebel Distributors Corp2003-09-16Not applicableUs
Nefazodone Hydrochloridetablet200 mg/1oralTeva Pharmaceuticals USA Inc2003-09-16Not applicableUs
Nefazodone Hydrochloridetablet100 mg/1oralREMEDYREPACK INC.2011-06-08Not applicableUs
Nefazodone Hydrochloridetablet100 mg/1oralSTAT Rx USA LLC2010-08-18Not applicableUs
Nefazodone Hydrochloridetablet250 mg/1oralRebel Distributors Corp2003-09-16Not applicableUs
Nefazodone Hydrochloridetablet250 mg/1oralTeva Pharmaceuticals USA Inc2003-09-16Not applicableUs
Nefazodone Hydrochloridetablet100 mg/1oralRebel Distributors Corp2003-09-16Not applicableUs
Nefazodone Hydrochloridetablet250 mg/1oralAv Kare, Inc.2013-07-30Not applicableUs
Nefazodone Hydrochloridetablet150 mg/1oralTeva Pharmaceuticals USA Inc2003-09-16Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DutoninNot Available
SerzoneNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Nefazodone Hydrochloride
82752-99-6
Thumb
  • InChI Key: DYCKFEBIOUQECE-UHFFFAOYSA-N
  • Monoisotopic Mass: 505.201130739
  • Average Mass: 506.468
DBSALT000406
Categories
UNII59H4FCV1TF
CAS number83366-66-9
WeightAverage: 470.007
Monoisotopic: 469.224453
Chemical FormulaC25H32ClN5O2
InChI KeyInChIKey=VRBKIVRKKCLPHA-UHFFFAOYSA-N
InChI
InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3
IUPAC Name
1-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-3-ethyl-4-(2-phenoxyethyl)-4,5-dihydro-1H-1,2,4-triazol-5-one
SMILES
CCC1=NN(CCCN2CCN(CC2)C2=CC(Cl)=CC=C2)C(=O)N1CCOC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenylpiperazine
  • Substituted aniline
  • Dialkylarylamine
  • Phenol ether
  • N-alkylpiperazine
  • Halobenzene
  • Chlorobenzene
  • Aniline
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of depression.
PharmacodynamicsNefazodone, an antidepressant synthetically derived phenylpiperazine, is used to treat major depression. Although it is structurally similar to trazodone, nefazodone has a mechanism of action different from other antidepressants and, hence, lacks the risk for major cardiovascular toxicity seen with tricyclics and insomnia and inhibition of REM sleep seen with the selective serotonin reuptake inhibitors.
Mechanism of actionWithin the serotonergic system, nefazodone acts as an antagonist at type 2 serotonin (5-HT2) post-synaptic receptors and, like fluoxetine-type antidepressants, inhibits pre-synaptic serotonin (5-HT) reuptake. These mechanisms increase the amount of serotonin available to interact with 5-HT receptors. Within the noradrenergic system, nefazodone inhibits norepinephrine uptake minimally. Nefazodone also antagonizes alpha(1)-adrenergic receptors, producing sedation, muscle relaxation, and a variety of cardiovascular effects. Nefazodone's affinity for benzodiazepine, cholinergic, dopaminergic, histaminic, and beta or alpha(2)-adrenergic receptors is not significant.
Related Articles
AbsorptionNefazodone is rapidly and completely absorbed. Its absolute bioavailability is low (about 20%).
Volume of distribution
  • 0.22 to 0.87 L/kg
Protein bindingGreater than 99% (in vitro, human plasma proteins).
Metabolism

Hepatic.

SubstrateEnzymesProduct
Nefazodone
hydroxynefazodoneDetails
Route of eliminationNefazodone is extensively metabolized after oral administration by n-dealkylation and aliphatic and aromatic hydroxylation, and less than 1% of administered nefazodone is excreted unchanged in urine.
Half life2-4 hours
ClearanceNot Available
ToxicityCases of life-threatening hepatic failure have been reported in patients treated with nefazodone.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9744
Caco-2 permeable+0.5296
P-glycoprotein substrateSubstrate0.5809
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.8373
Renal organic cation transporterInhibitor0.5685
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7506
CYP450 1A2 substrateNon-inhibitor0.7931
CYP450 2C9 inhibitorInhibitor0.5999
CYP450 2D6 inhibitorNon-inhibitor0.8799
CYP450 2C19 inhibitorNon-inhibitor0.5434
CYP450 3A4 inhibitorNon-inhibitor0.8711
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8028
Ames testNon AMES toxic0.5208
CarcinogenicityNon-carcinogens0.7388
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9067 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8749
hERG inhibition (predictor II)Inhibitor0.7288
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral100 mg/1
Tabletoral150 mg/1
Tabletoral200 mg/1
Tabletoral250 mg/1
Tabletoral50 mg/1
Tabletoral100 mg
Tabletoral150 mg
Tabletoral200 mg
Tabletoral50 mg
Prices
Unit descriptionCostUnit
Nefazodone hcl 250 mg tablet1.82USD tablet
Nefazodone hcl 200 mg tablet1.78USD tablet
Nefazodone hcl 150 mg tablet1.75USD tablet
Nefazodone hcl 100 mg tablet1.72USD tablet
Nefazodone hcl 50 mg tablet1.68USD tablet
Serzone 100 mg tablet1.53USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point83.5 °CPhysProp
logP4.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0698 mg/mLALOGPS
logP3.71ALOGPS
logP4.65ChemAxon
logS-3.8ALOGPS
pKa (Strongest Basic)7.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area51.62 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity132.38 m3·mol-1ChemAxon
Polarizability51.85 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0uk9-9846000000-49cb6e97c09a9e806dd5View in MoNA
References
Synthesis Reference

DrugSyn.org

US4338317
General References
  1. Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. [PubMed:9098663 ]
External Links
ATC CodesN06AX06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (152 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Nefazodone can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Nefazodone can be increased when it is combined with 3,4-Dichloroisocoumarin.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Nefazodone can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Nefazodone.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Nefazodone.
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Nefazodone.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Nefazodone.
AcepromazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Nefazodone.
AcetophenazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Acetophenazine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Nefazodone.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Nefazodone.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Nefazodone.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Nefazodone.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Nefazodone.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Nefazodone.
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Nefazodone.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Nefazodone.
AliskirenThe metabolism of Aliskiren can be decreased when combined with Nefazodone.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Nefazodone.
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Nefazodone.
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Nefazodone.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Nefazodone.
AlogliptinThe serum concentration of Nefazodone can be increased when it is combined with Alogliptin.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Nefazodone.
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Nefazodone.
Alpha-1-proteinase inhibitorThe serum concentration of Nefazodone can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Nefazodone.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Nefazodone.
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Nefazodone.
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Nefazodone.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Nefazodone.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Nefazodone.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Nefazodone.
AmisulprideThe risk or severity of adverse effects can be increased when Nefazodone is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Nefazodone.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Nefazodone.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Nefazodone.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Nefazodone.
AmperozideThe risk or severity of adverse effects can be increased when Nefazodone is combined with Amperozide.
AmprenavirThe serum concentration of Nefazodone can be increased when it is combined with Amprenavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Nefazodone.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Nefazodone.
Antithrombin III humanThe serum concentration of Nefazodone can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Nefazodone.
ApremilastThe metabolism of Apremilast can be decreased when combined with Nefazodone.
AprepitantThe serum concentration of Nefazodone can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Nefazodone.
AprotininThe serum concentration of Nefazodone can be increased when it is combined with Aprotinin.
ArgatrobanThe serum concentration of Nefazodone can be increased when it is combined with Argatroban.
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Nefazodone.
AripiprazoleThe risk or severity of adverse effects can be increased when Nefazodone is combined with Aripiprazole.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Nefazodone.
ArtemetherThe metabolism of Artemether can be decreased when combined with Nefazodone.
AsenapineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Asenapine.
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Nefazodone.
AsunaprevirThe serum concentration of Nefazodone can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Nefazodone can be increased when it is combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Nefazodone.
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Nefazodone.
AtomoxetineThe metabolism of Nefazodone can be decreased when combined with Atomoxetine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Nefazodone.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Nefazodone.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Nefazodone.
AzaperoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Azaperone.
AzelastineThe metabolism of Azelastine can be decreased when combined with Nefazodone.
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Nefazodone.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Nefazodone.
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Nefazodone.
BatimastatThe serum concentration of Nefazodone can be increased when it is combined with Batimastat.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Nefazodone.
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Nefazodone.
BenazeprilThe serum concentration of Nefazodone can be increased when it is combined with Benazepril.
BenzamidineThe serum concentration of Nefazodone can be increased when it is combined with Benzamidine.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Nefazodone.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Nefazodone.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Nefazodone.
BetaxololThe metabolism of Nefazodone can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Nefazodone can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Nefazodone.
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Nefazodone.
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Nefazodone.
BifeprunoxThe risk or severity of adverse effects can be increased when Nefazodone is combined with Bifeprunox.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Nefazodone.
BivalirudinThe serum concentration of Nefazodone can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Nefazodone can be increased when it is combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Nefazodone.
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Nefazodone.
BortezomibThe metabolism of Nefazodone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Nefazodone can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Nefazodone.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nefazodone.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nefazodone.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Nefazodone is combined with Brexpiprazole.
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Nefazodone.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Nefazodone.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Nefazodone.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nefazodone.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Nefazodone.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Nefazodone.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Nefazodone.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Nefazodone.
BupropionThe metabolism of Bupropion can be decreased when combined with Nefazodone.
BuspironeThe metabolism of Buspirone can be decreased when combined with Nefazodone.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Nefazodone.
BusulfanThe metabolism of Busulfan can be decreased when combined with Nefazodone.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Nefazodone.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Nefazodone.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Nefazodone.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Nefazodone.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Nefazodone.
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Nefazodone.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Nefazodone.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Nefazodone.
CandoxatrilThe serum concentration of Nefazodone can be increased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Nefazodone can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Nefazodone.
CarbamazepineThe metabolism of Nefazodone can be increased when combined with Carbamazepine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Nefazodone.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Nefazodone.
CariprazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Cariprazine.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Nefazodone.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Nefazodone.
CeliprololThe metabolism of Celiprolol can be decreased when combined with Nefazodone.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Nefazodone.
CeritinibThe serum concentration of Nefazodone can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Nefazodone.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Nefazodone.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Nefazodone.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Nefazodone.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Nefazodone.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Nefazodone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Chlorpromazine.
ChlorpromazineThe metabolism of Nefazodone can be decreased when combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Nefazodone.
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Nefazodone.
ChymostatinThe serum concentration of Nefazodone can be increased when it is combined with Chymostatin.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Nefazodone.
CilastatinThe serum concentration of Nefazodone can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Nefazodone can be increased when it is combined with Cilazapril.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Nefazodone.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Nefazodone.
CimetidineThe metabolism of Nefazodone can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Nefazodone.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Nefazodone.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Nefazodone.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Nefazodone.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Nefazodone.
CitalopramThe metabolism of Nefazodone can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Nefazodone can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Nefazodone.
ClemastineThe metabolism of Nefazodone can be decreased when combined with Clemastine.
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Nefazodone.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Nefazodone.
ClobazamThe metabolism of Nefazodone can be decreased when combined with Clobazam.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Nefazodone.
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Nefazodone.
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Nefazodone.
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Nefazodone.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Nefazodone.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Nefazodone.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Nefazodone.
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Nefazodone.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Nefazodone.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Nefazodone.
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Nefazodone.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Nefazodone.
ClotrimazoleThe metabolism of Nefazodone can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Clozapine can be decreased when combined with Nefazodone.
CobicistatThe serum concentration of Nefazodone can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Nefazodone.
CocaineThe metabolism of Cocaine can be decreased when combined with Nefazodone.
CodeineThe metabolism of Codeine can be decreased when combined with Nefazodone.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Nefazodone.
ConivaptanThe serum concentration of Nefazodone can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Nefazodone.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Nefazodone.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Nefazodone.
CrizotinibThe metabolism of Nefazodone can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Cyamemazine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Nefazodone.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nefazodone.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Nefazodone.
CyclosporineThe metabolism of Nefazodone can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Nefazodone.
CytarabineThe metabolism of Cytarabine can be decreased when combined with Nefazodone.
Dabigatran etexilateThe serum concentration of Nefazodone can be increased when it is combined with Dabigatran etexilate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Nefazodone.
DabrafenibThe serum concentration of Nefazodone can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Nefazodone.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Nefazodone.
DantroleneThe metabolism of Dantrolene can be decreased when combined with Nefazodone.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Nefazodone.
DapiprazoleThe risk or severity of adverse effects can be increased when Nefazodone is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Nefazodone.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Nefazodone.
DapsoneThe metabolism of Dapsone can be decreased when combined with Nefazodone.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Nefazodone.
DarunavirThe serum concentration of Nefazodone can be increased when it is combined with Darunavir.
DarunavirThe metabolism of Darunavir can be decreased when combined with Nefazodone.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Nefazodone.
DasatinibThe serum concentration of Nefazodone can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Nefazodone.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Nefazodone.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Nefazodone.
DeferasiroxThe serum concentration of Nefazodone can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Nefazodone.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Nefazodone.
DelavirdineThe metabolism of Nefazodone can be decreased when combined with Delavirdine.
DesipramineThe metabolism of Nefazodone can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Desipramine.
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Nefazodone.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Nefazodone.
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Nefazodone.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Nefazodone.
DexamethasoneThe serum concentration of Nefazodone can be decreased when it is combined with Dexamethasone.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Nefazodone.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Nefazodone.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Nefazodone.
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Nefazodone.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Nefazodone.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Nefazodone.
DienogestThe serum concentration of Dienogest can be increased when it is combined with Nefazodone.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Nefazodone.
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Nefazodone.
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Nefazodone.
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Nefazodone.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Nefazodone.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nefazodone.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Nefazodone.
DihydroergotamineThe metabolism of Nefazodone can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Nefazodone.
DiltiazemThe metabolism of Nefazodone can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Nefazodone.
DiphenhydramineThe metabolism of Nefazodone can be decreased when combined with Diphenhydramine.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Nefazodone.
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Nefazodone.
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Nefazodone.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Nefazodone.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Nefazodone.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Nefazodone.
DolasetronDolasetron may increase the serotonergic activities of Nefazodone.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Nefazodone.
DonepezilThe metabolism of Donepezil can be decreased when combined with Nefazodone.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Nefazodone.
DoxepinThe metabolism of Doxepin can be decreased when combined with Nefazodone.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Nefazodone.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Nefazodone.
DoxycyclineThe metabolism of Nefazodone can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Nefazodone.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Nefazodone.
DronedaroneThe metabolism of Nefazodone can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Nefazodone is combined with Droperidol.
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Nefazodone.
DuloxetineThe metabolism of Nefazodone can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Duloxetine.
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Nefazodone.
EcabetThe serum concentration of Nefazodone can be increased when it is combined with Ecabet.
EdoxabanThe serum concentration of Nefazodone can be increased when it is combined with Edoxaban.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Nefazodone.
EfavirenzThe serum concentration of Nefazodone can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Nefazodone.
ElafinThe serum concentration of Nefazodone can be increased when it is combined with Elafin.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Nefazodone.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Nefazodone.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Nefazodone.
EliglustatThe metabolism of Nefazodone can be decreased when combined with Eliglustat.
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Nefazodone.
EnalaprilThe serum concentration of Nefazodone can be increased when it is combined with Enalapril.
EnalaprilThe metabolism of Enalapril can be decreased when combined with Nefazodone.
EnalaprilatThe serum concentration of Nefazodone can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Nefazodone can be increased when it is combined with Enalkiren.
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Nefazodone.
EnzalutamideThe serum concentration of Nefazodone can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Nefazodone.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Nefazodone.
EquileninThe serum concentration of Equilenin can be increased when it is combined with Nefazodone.
EquilinThe serum concentration of Equilin can be increased when it is combined with Nefazodone.
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Nefazodone.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Nefazodone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Nefazodone.
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Nefazodone.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Nefazodone.
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Nefazodone.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Nefazodone.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Nefazodone.
ErythromycinThe metabolism of Nefazodone can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Nefazodone.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Nefazodone.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Nefazodone.
Eslicarbazepine acetateThe serum concentration of Nefazodone can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Nefazodone.
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Nefazodone.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Nefazodone.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Nefazodone.
EstramustineThe metabolism of Estramustine can be decreased when combined with Nefazodone.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Nefazodone.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Nefazodone.
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Nefazodone.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Nefazodone.
EthanolThe metabolism of Ethanol can be decreased when combined with Nefazodone.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Nefazodone.
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Nefazodone.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Nefazodone.
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Nefazodone.
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Nefazodone.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Nefazodone.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Nefazodone.
EtravirineThe serum concentration of Nefazodone can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Nefazodone.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nefazodone.
ExemestaneThe metabolism of Exemestane can be decreased when combined with Nefazodone.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Nefazodone.
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Nefazodone.
FelbamateThe metabolism of Felbamate can be decreased when combined with Nefazodone.
FelodipineThe metabolism of Felodipine can be decreased when combined with Nefazodone.
FencamfamineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fencamfamine.
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Nefazodone.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Nefazodone.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Nefazodone.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nefazodone.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Nefazodone.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Nefazodone.
FinasterideThe metabolism of Finasteride can be decreased when combined with Nefazodone.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Nefazodone.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Nefazodone.
FluconazoleThe metabolism of Nefazodone can be decreased when combined with Fluconazole.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Nefazodone.
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Nefazodone.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Nefazodone.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Nefazodone.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Nefazodone.
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Nefazodone.
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Nefazodone.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Nefazodone.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Nefazodone.
FlupentixolThe risk or severity of adverse effects can be increased when Nefazodone is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fluphenazine.
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Nefazodone.
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Nefazodone.
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Nefazodone.
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Nefazodone.
FluspirileneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fluspirilene.
FlutamideThe metabolism of Flutamide can be decreased when combined with Nefazodone.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Nefazodone.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Nefazodone.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Nefazodone.
FluvoxamineThe metabolism of Nefazodone can be decreased when combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fluvoxamine.
FosamprenavirThe metabolism of Nefazodone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Nefazodone can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Nefazodone can be increased when it is combined with Fosinopril.
FosphenytoinThe metabolism of Nefazodone can be increased when combined with Fosphenytoin.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Nefazodone.
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Nefazodone.
Fusidic AcidThe serum concentration of Nefazodone can be increased when it is combined with Fusidic Acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Nefazodone.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Nefazodone.
GeldanamycinThe serum concentration of Nefazodone can be increased when it is combined with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Nefazodone.
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Nefazodone.
GlipizideThe metabolism of Glipizide can be decreased when combined with Nefazodone.
GlyburideThe metabolism of Glyburide can be decreased when combined with Nefazodone.
GM6001The serum concentration of Nefazodone can be increased when it is combined with GM6001.
GranisetronThe metabolism of Granisetron can be decreased when combined with Nefazodone.
GranisetronGranisetron may increase the serotonergic activities of Nefazodone.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Nefazodone.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Nefazodone.
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Nefazodone.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Nefazodone.
HaloperidolThe risk or severity of adverse effects can be increased when Nefazodone is combined with Haloperidol.
HaloperidolThe metabolism of Nefazodone can be decreased when combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Nefazodone.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Nefazodone.
HirulogThe serum concentration of Nefazodone can be increased when it is combined with Hirulog.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Nefazodone.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Nefazodone.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Nefazodone.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Nefazodone.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Nefazodone.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Nefazodone.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Nefazodone.
IdelalisibThe serum concentration of Nefazodone can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Nefazodone resulting in a loss in efficacy.
IloperidoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Iloperidone.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Nefazodone.
ImatinibThe metabolism of Nefazodone can be decreased when combined with Imatinib.
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Nefazodone.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Nefazodone.
ImipramineThe metabolism of Nefazodone can be decreased when combined with Imipramine.
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Nefazodone.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Nefazodone.
IndapamideThe metabolism of Indapamide can be decreased when combined with Nefazodone.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Nefazodone.
IndinavirThe metabolism of Nefazodone can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Nefazodone.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Nefazodone.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Nefazodone.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Nefazodone.
IsavuconazoniumThe metabolism of Nefazodone can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Nefazodone is combined with Isocarboxazid.
IsoflurophateThe serum concentration of Nefazodone can be increased when it is combined with Isoflurophate.
IsoniazidThe metabolism of Nefazodone can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Nefazodone.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Nefazodone.
IsradipineThe metabolism of Nefazodone can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Nefazodone.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Nefazodone.
IvacaftorThe serum concentration of Nefazodone can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Nefazodone.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Nefazodone.
IxazomibThe serum concentration of Nefazodone can be increased when it is combined with Ixazomib.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Nefazodone.
KetamineThe metabolism of Ketamine can be decreased when combined with Nefazodone.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Nefazodone.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Nefazodone.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Nefazodone.
KetoconazoleThe metabolism of Nefazodone can be decreased when combined with Ketoconazole.
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Nefazodone.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Nefazodone.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Nefazodone.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Nefazodone.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Nefazodone.
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Nefazodone.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Nefazodone.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Nefazodone.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Nefazodone.
LepirudinThe serum concentration of Nefazodone can be increased when it is combined with Lepirudin.
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Nefazodone.
LetrozoleThe metabolism of Letrozole can be decreased when combined with Nefazodone.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Nefazodone.
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Nefazodone.
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Nefazodone.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Nefazodone.
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Nefazodone.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Nefazodone.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Nefazodone.
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Nefazodone.
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Nefazodone.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Nefazodone.
LinagliptinThe serum concentration of Nefazodone can be increased when it is combined with Linagliptin.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Nefazodone.
LinezolidLinezolid may increase the serotonergic activities of Nefazodone.
LinezolidThe risk or severity of adverse effects can be increased when Nefazodone is combined with Linezolid.
LisinoprilThe serum concentration of Nefazodone can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Nefazodone.
LithiumThe risk or severity of adverse effects can be increased when Nefazodone is combined with Lithium.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Nefazodone.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Nefazodone.
LopinavirThe serum concentration of Nefazodone can be increased when it is combined with Lopinavir.
LopinavirThe metabolism of Lopinavir can be decreased when combined with Nefazodone.
LoratadineThe metabolism of Loratadine can be decreased when combined with Nefazodone.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Nefazodone.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Nefazodone.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Nefazodone.
LovastatinThe metabolism of Nefazodone can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Loxapine.
LuliconazoleThe serum concentration of Nefazodone can be increased when it is combined with Luliconazole.
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Nefazodone.
LumefantrineThe metabolism of Nefazodone can be decreased when combined with Lumefantrine.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Nefazodone.
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Nefazodone.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Nefazodone.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Nefazodone.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Nefazodone.
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Nefazodone.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Nefazodone.
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Nefazodone.
MefloquineThe metabolism of Mefloquine can be decreased when combined with Nefazodone.
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Nefazodone.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Nefazodone.
MelperoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Melperone.
MesoridazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Mesoridazine.
MethadoneThe metabolism of Methadone can be decreased when combined with Nefazodone.
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Nefazodone.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Nefazodone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Methotrimeprazine.
MethotrimeprazineThe metabolism of Nefazodone can be decreased when combined with Methotrimeprazine.
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Nefazodone.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Nefazodone.
Methylene blueNefazodone may increase the serotonergic activities of Methylene blue.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Nefazodone.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Nefazodone.
MetoclopramideThe risk or severity of adverse effects can be increased when Nefazodone is combined with Metoclopramide.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Nefazodone.
MetoprololThe metabolism of Nefazodone can be decreased when combined with Metoprolol.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Nefazodone.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Nefazodone.
MianserinThe metabolism of Mianserin can be decreased when combined with Nefazodone.
MibefradilThe metabolism of Mibefradil can be decreased when combined with Nefazodone.
MiconazoleThe metabolism of Miconazole can be decreased when combined with Nefazodone.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Nefazodone.
MifepristoneThe serum concentration of Mifepristone can be increased when it is combined with Nefazodone.
MifepristoneThe metabolism of Nefazodone can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Nefazodone is combined with Milnacipran.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Nefazodone.
MirabegronThe metabolism of Nefazodone can be decreased when combined with Mirabegron.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Nefazodone.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Nefazodone.
MitotaneThe serum concentration of Nefazodone can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Nefazodone.
MoclobemideThe risk or severity of adverse effects can be increased when Nefazodone is combined with Moclobemide.
ModafinilThe serum concentration of Nefazodone can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be decreased when combined with Nefazodone.
MoexiprilThe serum concentration of Nefazodone can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Molindone.
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Nefazodone.
MontelukastThe metabolism of Montelukast can be decreased when combined with Nefazodone.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Nefazodone.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Nefazodone.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Nefazodone can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NadololThe serum concentration of Nadolol can be decreased when it is combined with Nefazodone.
NafcillinThe serum concentration of Nefazodone can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nefazodone.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Nefazodone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Nefazodone.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Nefazodone.
NCX 4016The serum concentration of Nefazodone can be increased when it is combined with NCX 4016.
NelfinavirThe serum concentration of Nefazodone can be increased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Nefazodone.
NetupitantThe serum concentration of Nefazodone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Nefazodone can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Nefazodone.
NicardipineThe metabolism of Nefazodone can be decreased when combined with Nicardipine.
NicotineThe metabolism of Nicotine can be decreased when combined with Nefazodone.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Nefazodone.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Nefazodone.
NilotinibThe metabolism of Nefazodone can be decreased when combined with Nilotinib.
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Nefazodone.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Nefazodone.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Nefazodone.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Nefazodone.
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Nefazodone.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Nefazodone.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Nefazodone.
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Nefazodone.
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Nefazodone.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Nefazodone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Nefazodone.
OlanzapineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Olanzapine.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Nefazodone.
OlaparibThe metabolism of Nefazodone can be decreased when combined with Olaparib.
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Nefazodone.
OmapatrilatThe serum concentration of Nefazodone can be increased when it is combined with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Nefazodone.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Nefazodone.
OndansetronThe risk or severity of adverse effects can be increased when Nefazodone is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Nefazodone.
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Nefazodone.
OsanetantThe risk or severity of adverse effects can be increased when Nefazodone is combined with Osanetant.
OsimertinibThe serum concentration of Nefazodone can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Nefazodone.
OtamixabanThe serum concentration of Nefazodone can be increased when it is combined with Otamixaban.
OxazepamThe metabolism of Oxazepam can be decreased when combined with Nefazodone.
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Nefazodone.
OxycodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Oxycodone.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Nefazodone.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Nefazodone.
PalbociclibThe serum concentration of Nefazodone can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Paliperidone.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Nefazodone.
PalonosetronPalonosetron may increase the serotonergic activities of Nefazodone.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Nefazodone.
PanobinostatThe metabolism of Nefazodone can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Nefazodone.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Nefazodone.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Nefazodone.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Nefazodone.
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Nefazodone.
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Nefazodone.
ParoxetineThe metabolism of Nefazodone can be decreased when combined with Paroxetine.
ParoxetineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Nefazodone.
Peginterferon alfa-2bThe serum concentration of Nefazodone can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Nefazodone.
PentobarbitalThe metabolism of Nefazodone can be increased when combined with Pentobarbital.
PerampanelThe metabolism of Perampanel can be decreased when combined with Nefazodone.
PergolideThe metabolism of Pergolide can be decreased when combined with Nefazodone.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Nefazodone.
PerindoprilThe serum concentration of Nefazodone can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be decreased when combined with Nefazodone.
PerospironeThe risk or severity of adverse effects can be increased when Nefazodone is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Perphenazine.
PethidineThe metabolism of Pethidine can be decreased when combined with Nefazodone.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Nefazodone.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Nefazodone.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Nefazodone.
PhenobarbitalThe metabolism of Nefazodone can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Nefazodone.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Nefazodone.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Nefazodone.
PhenytoinThe metabolism of Nefazodone can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Nefazodone.
PhosphoramidonThe serum concentration of Nefazodone can be increased when it is combined with Phosphoramidon.
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Nefazodone.
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Nefazodone.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Nefazodone.
PinacidilThe metabolism of Pinacidil can be decreased when combined with Nefazodone.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Nefazodone.
PipamperoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Pipotiazine.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Nefazodone.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Nefazodone.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Nefazodone.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Nefazodone.
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Nefazodone.
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Nefazodone.
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Nefazodone resulting in a loss in efficacy.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Nefazodone.
PrazepamThe metabolism of Prazepam can be decreased when combined with Nefazodone.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Nefazodone.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Nefazodone.
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Nefazodone.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Nefazodone.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Nefazodone.
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Nefazodone.
PrimaquineThe metabolism of Primaquine can be decreased when combined with Nefazodone.
PrimidoneThe metabolism of Nefazodone can be increased when combined with Primidone.
PrinomastatThe serum concentration of Nefazodone can be increased when it is combined with Prinomastat.
ProcarbazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Nefazodone.
ProguanilThe metabolism of Proguanil can be decreased when combined with Nefazodone.
PromazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Promazine.
PromazineThe metabolism of Nefazodone can be decreased when combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Nefazodone.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Nefazodone.
PropericiazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Propericiazine.
PropofolThe metabolism of Propofol can be decreased when combined with Nefazodone.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Nefazodone.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Nefazodone.
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Nefazodone.
QuazepamThe metabolism of Quazepam can be decreased when combined with Nefazodone.
QuetiapineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Quetiapine.
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Nefazodone.
QuinaprilThe serum concentration of Nefazodone can be increased when it is combined with Quinapril.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Nefazodone.
QuinidineThe metabolism of Nefazodone can be decreased when combined with Quinidine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Nefazodone.
QuinineThe metabolism of Nefazodone can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Nefazodone.
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Nefazodone.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Nefazodone.
RamiprilThe serum concentration of Nefazodone can be increased when it is combined with Ramipril.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Nefazodone.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nefazodone.
RanolazineThe metabolism of Nefazodone can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Rasagiline.
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Nefazodone.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Nefazodone.
RemikirenThe serum concentration of Nefazodone can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Nefazodone is combined with Remoxipride.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Nefazodone.
ReserpineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Reserpine.
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Nefazodone.
RifabutinThe metabolism of Nefazodone can be increased when combined with Rifabutin.
RifampicinThe metabolism of Nefazodone can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Nefazodone.
RifapentineThe metabolism of Nefazodone can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Nefazodone.
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Nefazodone.
RimonabantThe metabolism of Rimonabant can be decreased when combined with Nefazodone.
RiociguatThe metabolism of Riociguat can be decreased when combined with Nefazodone.
RisperidoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Risperidone.
RitonavirThe serum concentration of Nefazodone can be increased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Nefazodone.
RivaroxabanThe serum concentration of Nefazodone can be increased when it is combined with Rivaroxaban.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Nefazodone.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Nefazodone.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Nefazodone.
RolapitantThe metabolism of Rolapitant can be decreased when combined with Nefazodone.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Nefazodone.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Nefazodone.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Nefazodone.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Nefazodone.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Nefazodone.
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Nefazodone.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Nefazodone.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Nefazodone.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Nefazodone.
SaquinavirThe serum concentration of Nefazodone can be increased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Nefazodone.
SaxagliptinThe serum concentration of Nefazodone can be increased when it is combined with Saxagliptin.
SelegilineThe metabolism of Selegiline can be decreased when combined with Nefazodone.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Nefazodone.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Nefazodone.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Nefazodone.
SertindoleThe risk or severity of adverse effects can be increased when Nefazodone is combined with Sertindole.
SertralineThe metabolism of Sertraline can be decreased when combined with Nefazodone.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Nefazodone.
SibutramineThe metabolism of Sibutramine can be decreased when combined with Nefazodone.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Nefazodone.
SildenafilThe metabolism of Nefazodone can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nefazodone.
SiltuximabThe serum concentration of Nefazodone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Nefazodone can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Nefazodone.
SirolimusThe metabolism of Sirolimus can be decreased when combined with Nefazodone.
SitagliptinThe serum concentration of Nefazodone can be increased when it is combined with Sitagliptin.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Nefazodone.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Nefazodone.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Nefazodone.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Nefazodone.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Nefazodone.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Nefazodone.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Nefazodone.
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Nefazodone.
SpiraprilThe serum concentration of Nefazodone can be increased when it is combined with Spirapril.
St. John's WortThe serum concentration of Nefazodone can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Nefazodone can be increased when it is combined with Stiripentol.
SufentanilThe metabolism of Sufentanil can be decreased when combined with Nefazodone.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Nefazodone.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Nefazodone.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Nefazodone.
SulfisoxazoleThe metabolism of Nefazodone can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Nefazodone is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Nefazodone.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Nefazodone.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Nefazodone.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Nefazodone.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Nefazodone.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Nefazodone.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Nefazodone.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Nefazodone.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Nefazodone.
TapentadolThe risk or severity of adverse effects can be increased when Nefazodone is combined with Tapentadol.
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Nefazodone.
TasosartanThe metabolism of Tasosartan can be decreased when combined with Nefazodone.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Nefazodone.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Nefazodone.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Nefazodone.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Nefazodone.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Nefazodone is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Nefazodone can be increased when it is combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Nefazodone.
TelithromycinThe metabolism of Nefazodone can be decreased when combined with Telithromycin.
TemazepamThe metabolism of Temazepam can be decreased when combined with Nefazodone.
TemocaprilThe serum concentration of Nefazodone can be increased when it is combined with Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Nefazodone.
TeniposideThe metabolism of Teniposide can be decreased when combined with Nefazodone.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Nefazodone.
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Nefazodone.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Nefazodone.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Nefazodone.
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Nefazodone.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Nefazodone.
ThioproperazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Nefazodone.
ThioridazineThe metabolism of Nefazodone can be decreased when combined with Thioridazine.
ThiorphanThe serum concentration of Nefazodone can be increased when it is combined with Thiorphan.
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Nefazodone.
ThiothixeneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Thiothixene.
TiagabineThe metabolism of Tiagabine can be decreased when combined with Nefazodone.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Nefazodone resulting in a loss in efficacy.
TiclopidineThe metabolism of Nefazodone can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be decreased when it is combined with Nefazodone.
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Nefazodone.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Nefazodone.
TipranavirThe serum concentration of Nefazodone can be increased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Nefazodone.
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Nefazodone.
TocilizumabThe serum concentration of Nefazodone can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Nefazodone.
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Nefazodone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nefazodone.
TopotecanThe serum concentration of Topotecan can be decreased when it is combined with Nefazodone.
ToremifeneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Toremifene.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Nefazodone.
TramadolThe serum concentration of Tramadol can be increased when it is combined with Nefazodone.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Nefazodone.
TrandolaprilThe serum concentration of Nefazodone can be increased when it is combined with Trandolapril.
TranylcypromineThe metabolism of Nefazodone can be decreased when combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Nefazodone.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Nefazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Nefazodone.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Nefazodone.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Nefazodone.
TriazolamThe metabolism of Triazolam can be decreased when combined with Nefazodone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Nefazodone.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Nefazodone.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Nefazodone.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Nefazodone.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Nefazodone.
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Nefazodone.
UbenimexThe serum concentration of Nefazodone can be increased when it is combined with Ubenimex.
UdenafilThe metabolism of Udenafil can be decreased when combined with Nefazodone.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Nefazodone.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Nefazodone.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Nefazodone.
VandetanibThe metabolism of Vandetanib can be decreased when combined with Nefazodone.
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Nefazodone.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Nefazodone.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Nefazodone.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Nefazodone.
VenlafaxineThe metabolism of Nefazodone can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Nefazodone.
VerapamilThe metabolism of Nefazodone can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Nefazodone.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Nefazodone.
VilanterolThe metabolism of Vilanterol can be decreased when combined with Nefazodone.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Nefazodone.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Nefazodone.
VildagliptinThe serum concentration of Nefazodone can be increased when it is combined with Vildagliptin.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Nefazodone.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Nefazodone.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Nefazodone.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Nefazodone.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Nefazodone.
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Nefazodone.
VoriconazoleThe metabolism of Nefazodone can be decreased when combined with Voriconazole.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Nefazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Nefazodone.
WarfarinThe metabolism of Warfarin can be decreased when combined with Nefazodone.
XimelagatranThe serum concentration of Nefazodone can be increased when it is combined with Ximelagatran.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Nefazodone.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Nefazodone.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Nefazodone.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Nefazodone.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Nefazodone.
ZileutonThe metabolism of Zileuton can be decreased when combined with Nefazodone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Ziprasidone.
ZiprasidoneThe metabolism of Nefazodone can be decreased when combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Nefazodone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Nefazodone.
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Nefazodone.
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Nefazodone.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Nefazodone.
ZotepineThe risk or severity of adverse effects can be increased when Nefazodone is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Nefazodone is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid avocado.
  • Limit garlic, ginger, gingko, and horse chestnut.
  • Take this medication either consistently with or without food as instructed by your doctor.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Hidalgo R, Hertzberg MA, Mellman T, Petty F, Tucker P, Weisler R, Zisook S, Chen S, Churchill E, Davidson J: Nefazodone in post-traumatic stress disorder: results from six open-label trials. Int Clin Psychopharmacol. 1999 Mar;14(2):61-8. [PubMed:10220119 ]
  2. Meyer JH, Cho R, Kennedy S, Kapur S: The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET. Psychopharmacology (Berl). 1999 Jun;144(3):279-81. [PubMed:10435395 ]
  3. Horton JC, Trobe JD: Akinetopsia from nefazodone toxicity. Am J Ophthalmol. 1999 Oct;128(4):530-1. [PubMed:10577608 ]
  4. Eckler JR, Rabin RA, Winter JC: Nefazodone in the rat: mimicry and antagonism of [-]-DOM-induced stimulus control. Pharmacol Biochem Behav. 2003 May;75(2):405-10. [PubMed:12873632 ]
  5. Avila A, Cardona X, Martin-Baranera M, Maho P, Sastre F, Bello J: Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J Clin Psychopharmacol. 2003 Oct;23(5):509-13. [PubMed:14520130 ]
  6. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD: Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 1995;56 Suppl 6:3-11. [PubMed:7649970 ]
  7. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  8. Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. [PubMed:9098663 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Millan MJ: Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60. [PubMed:16433010 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Owens MJ, Ieni JR, Knight DL, Winders K, Nemeroff CB: The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Life Sci. 1995;57(24):PL373-80. [PubMed:7475971 ]
  2. Narayan M, Anderson G, Cellar J, Mallison RT, Price LH, Nelson JC: Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin. J Clin Psychopharmacol. 1998 Feb;18(1):67-71. [PubMed:9472845 ]
  3. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  4. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD: Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 1995;56 Suppl 6:3-11. [PubMed:7649970 ]
  5. Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. [PubMed:9098663 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Owens MJ, Ieni JR, Knight DL, Winders K, Nemeroff CB: The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Life Sci. 1995;57(24):PL373-80. [PubMed:7475971 ]
  2. Owen D, Du L, Bakish D, Lapierre YD, Hrdina PD: Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression. Psychiatry Res. 1999 Jul 30;87(1):1-5. [PubMed:10512149 ]
  3. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  4. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD: Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 1995;56 Suppl 6:3-11. [PubMed:7649970 ]
  5. Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. [PubMed:9098663 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  3. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD: Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 1995;56 Suppl 6:3-11. [PubMed:7649970 ]
  2. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. [PubMed:9098663 ]
  2. DeVane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L: Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol. 2004 Feb;24(1):4-10. [PubMed:14709940 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. von Moltke LL, Greenblatt DJ, Granda BW, Grassi JM, Schmider J, Harmatz JS, Shader RI: Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999 Jul;145(1):113-22. [PubMed:10445380 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. von Moltke LL, Greenblatt DJ, Granda BW, Grassi JM, Schmider J, Harmatz JS, Shader RI: Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999 Jul;145(1):113-22. [PubMed:10445380 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Not Available
Gene Name:
CYP2B
Uniprot ID:
Q14097
Molecular Weight:
43147.81 Da
References
  1. Haduch A, Wojcikowski J, Daniel WA: Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study. Pharmacol Rep. 2008 Nov-Dec;60(6):957-65. [PubMed:19211989 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ: P-glycoprotein interactions of nefazodone and trazodone in cell culture. J Clin Pharmacol. 2001 Jul;41(7):708-14. [PubMed:11452702 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23